Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, cancer and Type 1 diabetes. The IPSC news feed on Stock Titan aggregates company announcements, press releases and regulatory updates so readers can follow how Century Therapeutics communicates progress on its pipeline and corporate strategy.
According to the company’s public disclosures, key news themes include updates on clinical and preclinical programs such as CNTY-101 for B-cell-mediated autoimmune diseases, CNTY-308 as a CD19-targeted CAR-iT therapy, and CNTY-813, an iPSC-derived beta islet program for Type 1 diabetes. News items also cover scientific presentations at conferences, where Century Therapeutics shares data on Allo-Evasion™ 5.0, CAR-NK and CAR-T platforms, and iPSC-derived non-immune cell programs.
Investors and followers of IPSC can also find coverage of quarterly financial results, cash runway commentary, and organizational changes such as workforce adjustments, board appointments and executive role updates. Capital markets events, including private placement financings and participation in healthcare investment conferences, are typically disclosed through press releases and associated Form 8-K filings.
By reviewing the IPSC news stream, readers can see how Century Therapeutics describes the evolution of its iPSC cell foundry, its focus on B-cell-mediated diseases and oncology, and its efforts to advance off-the-shelf cell therapies. Bookmark this page to access a consolidated view of Century Therapeutics’ latest public communications as they are released.
Century Therapeutics (NASDAQ: IPSC) announced the participation of its senior management in a fireside chat ahead of the Piper Sandler 33rd Annual Virtual Healthcare Conference, scheduled for November 30 to December 2, 2021. A recording of the chat will be available today at 10:00 AM ET on the Events & Presentations section of Century's website, accessible for 30 days. The company focuses on developing iPSC-derived cell therapies aimed at overcoming challenges in cancer treatment.
Century Therapeutics (NASDAQ: IPSC) reported third-quarter financial results showing a net loss of $26 million, up from $13.1 million a year prior. Cash and equivalents decreased to $400.3 million from $440 million. Despite this, the company remains on track with its lead program, CNTY-101, for a mid-2022 IND filing. Notable investments have been made in manufacturing and R&D, with R&D expenses rising to $19.5 million due to increased personnel and study costs. A collaboration with Outpace Bio aims to enhance their iPSC therapy platform.
Century Therapeutics (NASDAQ: IPSC) announced the presentation of preclinical data from its CNTY-101 program at the 63rd American Society of Hematology Annual Meeting, taking place December 11-14, 2021, in Atlanta and virtually. The company will also host a virtual R&D update on December 16, 2021, featuring discussions on B-cell malignancies by Dr. Eduardo Sotomayor. Key poster presentations include iPSC-derived CAR-NK cells and Gamma Delta CAR-T cells for cancer immunotherapy, aiming to address limitations in current therapies.
Century Therapeutics (NASDAQ: IPSC) has announced a research collaboration with Outpace Bio focusing on enhanced CAR engineering for immuno-oncology. This partnership aims to optimize CAR functionality using Outpace's advanced protein design and synthetic biology technologies. The initial program will target hematological malignancies, with potential for future expansion. Century's CEO emphasized the importance of innovative cell engineering to advance next-generation therapies, while Outpace's CEO highlighted the collaboration's potential to improve the efficacy of T cell therapies.
Century Therapeutics (NASDAQ: IPSC) announced its inclusion in the Russell 2000 Index, effective September 20, 2021. This milestone highlights the company's progress in developing iPSC-derived cell therapies for cancer treatment. The Russell 2000 Index represents small-cap stocks and is used by investors and funds to benchmark performance. CEO Lalo Flores expressed optimism about reaching a broader investor base as the company advances its lead therapeutic program, CNTY-101, into clinical stages. The Russell Index includes approximately $10.6 trillion in assets.
Century Therapeutics (NASDAQ: IPSC) reported its second-quarter financial results for 2021, highlighting significant developments and financial positions. The company raised approximately $221 million in a recent IPO, with cash, cash equivalents, and marketable securities totaling $440 million as of June 30, 2021. R&D expenses increased to $18.9 million, while G&A expenses rose to $4.1 million. The net loss for the quarter was $23.3 million, compared to $15.3 million in Q2 2020. The lead program, CNTY-101, is on track for IND filing in mid-2022.
Century Therapeutics (NASDAQ: IPSC) has successfully closed its initial public offering, selling 12,132,500 shares at $20.00 per share, raising approximately $242.7 million before expenses. This includes the underwriters' option for additional shares. The offering was facilitated by J.P. Morgan, BofA Securities, SVB Leerink, and Piper Sandler. The funds will support the development of iPSC-derived cell therapies aimed at treating cancer. A registration statement was filed and effective on June 17, 2021.
Century Therapeutics has priced its initial public offering (IPO) at $20.00 per share, offering 10,550,000 shares of common stock, expected to generate gross proceeds of $211 million. The stock will begin trading on Nasdaq under the symbol 'IPSC' on June 18, 2021, with the offering closing on June 22, 2021. J.P. Morgan, BofA Securities, SVB Leerink, and Piper Sandler are managing the deal. Century focuses on developing iPSC-derived cell therapies for cancer treatment, aiming to enhance patient access and care efficiency.